Skip to search formSkip to main contentSkip to account menu

CI-1033

Known as: CI 1033, CI-1033/PD183805, CI1033 
An orally bioavailable quinazoline with potential antineoplastic and radiosensitizing activities. CI-1033 binds to the intracellular domains of pan… 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

Canertinibcanertinib dihydrochloride
PD 183805

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Erratum: Essential erbB family phosphorylation in osteosarcoma as a target for CI‐1033 inhibition
BACKGROUND The role of erbB tyrosine kinases, especially Her-2, in osteosarcoma has engendered intense debate. Some investigators… 
2010
2010
The pan-ErbB receptor tyrosine kinase inhibitor canertinib induces ErbB-independent apoptosis in human leukemia (HL-60 and U-937) cells.
2008
2008
Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033
Neurofibromatosis Type 1 (NF1) is characterized by the abnormal proliferation of neuroectodermal tissues and the development of… 
2006
2006
Multi-tracer small animal PET imaging of the tumour response to the novel pan-Erb-B inhibitor CI-1033
PurposeThis study was designed as “proof of concept” for a drug development model utilising multi-tracer serial small animal PET… 
2004
2004
A phase 2, single agent study of CI-1033 administered at two doses in ovarian cancer patients who failed platinum therapy.
5054 Background: Ovarian cancer that is refractory to platinum-based therapies is a therapeutic challenge, particularly in the… 
Review
2004
Review
2004
Searching for Reliable Epidermal Growth Factor Receptor Response Predictors
Many years before the term “molecular targeting” was popularized in cancer therapeutics, the epidermal growth factor (EGF) and… 
Review
2004
Review
2004
Epidermal growth factor receptor inhibitors: a new prospective in the treatment of lung cancer.
Lung cancer is the leading cause of death worldwide. Current treatment modalities, including chemotherapy, radiotherapy and… 
2003
2003
Skin as a surrogate tissue for pharmacodynamic end points: is it deep enough?
As the number of molecular-targeted agents under clinical development keeps growing, it is becoming increasingly evident that it… 
Review
2003
Review
2003
[Radiotherapy and inhibitors of epidermal growth factor receptor: preclinical findings and preliminary clinical trials].
Recent studies have demonstrated that ionizing radiation activate existing cellular response pathways involving protein kinases… 
Highly Cited
2001
Highly Cited
2001
Evidence for epidermal growth factor receptor-enhanced chemosensitivity in combinations of cisplatin and the new irreversible tyrosine kinase inhibitor CI-1033
Irreversible inhibitors of the epidermal growth factor receptor (EGFR) are showing promise in clinical trials. This report is the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)